Close Menu

Aegera Closes $15 Million Round of Financing

Aegera Therapeutics said this week that it has closed a $15 million Series C round of financing.

The financing, said the company, was led by VenGrowth Advanced Life Sciences Fund and included new and existing investors. Proceeds of the financing will be used to support the clinical development of Aegera’s lead product candidates, including a phase I antisense cancer drug.

FDA Grants Pharmion’s Demethylating MDS Drug Priority Review

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Guardian reports that the Mammalian Genetics Unit at the Harwell Institute is to close.

Scientific research itself contributes to plastic waste and isn't very sustainable, FiveThirtyEight reports.

Restaurants in the US may soon serve AquaBounty's genetically modified salmon, according to the Associated Press.

In Science this week: three studies from the Ruminant Genome Project, and more.